Injectable collagen scaffold with mesenchymal stem cells

Injectable collagen scaffold with mesenchymal stem cells is a regenerative therapy that combines a collagen-based scaffold with human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). This combination therapy has been investigated for various medical conditions including intracerebral hemorrhage, myocardial infarction, and liver cirrhosis. ## Mechanism and Composition The therapy consists of two main components: 1. Injectable collagen scaffold - provides a structural matrix that supports cell growth and tissue regeneration 2. Human umbilical cord-derived mesenchymal stem cells - contribute to tissue repair through their immunomodulatory and regenerative properties When implanted into damaged tissue, the collagen scaffold helps retain the transplanted stem cells at the injury site for longer periods, enhancing their therapeutic effect. The scaffold also provides a supportive environment for cell growth and tissue regeneration. ## Clinical Applications This therapy has been studied in several clinical contexts: - **Intracerebral Hemorrhage**: A non-randomized phase I clinical trial conducted between 2016-2020 showed that patients who received injectable collagen scaffold with hUC-MSCs had more significant improvements in activities of daily living and cognitive function, as well as smaller foci of intracerebral hemorrhage-related encephalomalacia compared to control groups[1]. - **Myocardial Infarction**: Research has indicated that the collagen scaffold promotes recovery from myocardial infarction by enabling long-term local retention of transplanted hUC-MSCs[3]. A study suggested that intramyocardial injection of collagen hydrogel with hUC-MSCs during coronary artery bypass grafting (CABG) is safe and feasible for treatment[4]. - **Liver Cirrhosis**: Clinical trials have been conducted to assess the safety and efficacy of injectable collagen scaffold combined with hUC-MSCs for patients with decompensated cirrhosis[6]. The therapy appears to be well-tolerated, with studies reporting no severe adverse events associated with the cell transplantation[1]. ## Development Status This therapeutic approach is still in clinical development for various indications, with most studies being early-phase clinical trials. The combination of injectable collagen scaffold with mesenchymal stem cells represents an emerging approach in regenerative medicine with potential applications across multiple medical conditions.

Brand names

Injectable Collagen Scaffold

Other names

Injectable collagen scaffold with hUC-MSCs